| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vaccination | 83 | 2025 | 655 | 9.370 |
Why?
|
| Vaccines | 33 | 2025 | 218 | 8.520 |
Why?
|
| Influenza Vaccines | 35 | 2025 | 273 | 3.380 |
Why?
|
| Humans | 206 | 2025 | 17822 | 3.340 |
Why?
|
| Immunization Schedule | 26 | 2025 | 122 | 3.320 |
Why?
|
| Vaccination Coverage | 10 | 2025 | 45 | 3.270 |
Why?
|
| Child | 84 | 2024 | 2497 | 2.990 |
Why?
|
| Health Knowledge, Attitudes, Practice | 18 | 2025 | 382 | 2.960 |
Why?
|
| Child, Preschool | 65 | 2025 | 1424 | 2.890 |
Why?
|
| Immunization Programs | 17 | 2022 | 65 | 2.810 |
Why?
|
| Infant | 66 | 2025 | 1198 | 2.760 |
Why?
|
| Immunization | 22 | 2024 | 70 | 2.710 |
Why?
|
| Adolescent | 82 | 2025 | 3690 | 2.490 |
Why?
|
| Papillomavirus Vaccines | 12 | 2022 | 113 | 2.440 |
Why?
|
| Influenza, Human | 24 | 2023 | 265 | 2.430 |
Why?
|
| United States | 83 | 2025 | 4007 | 2.420 |
Why?
|
| Female | 139 | 2025 | 12780 | 2.410 |
Why?
|
| Advisory Committees | 18 | 2024 | 113 | 2.400 |
Why?
|
| Male | 113 | 2025 | 10145 | 2.250 |
Why?
|
| Parents | 13 | 2023 | 297 | 2.060 |
Why?
|
| Papillomavirus Infections | 7 | 2022 | 139 | 2.040 |
Why?
|
| Practice Patterns, Physicians' | 17 | 2024 | 332 | 1.980 |
Why?
|
| Electronic Health Records | 18 | 2025 | 698 | 1.920 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 14 | 2022 | 93 | 1.720 |
Why?
|
| Pediatrics | 17 | 2020 | 161 | 1.670 |
Why?
|
| Adult | 74 | 2025 | 7708 | 1.670 |
Why?
|
| Reminder Systems | 7 | 2016 | 80 | 1.590 |
Why?
|
| Patient Acceptance of Health Care | 14 | 2022 | 391 | 1.580 |
Why?
|
| Practice Guidelines as Topic | 15 | 2024 | 321 | 1.560 |
Why?
|
| Colorado | 28 | 2020 | 164 | 1.550 |
Why?
|
| School Health Services | 10 | 2014 | 39 | 1.440 |
Why?
|
| Retrospective Studies | 32 | 2024 | 2467 | 1.420 |
Why?
|
| Internet | 5 | 2024 | 231 | 1.420 |
Why?
|
| Social Media | 2 | 2021 | 12 | 1.300 |
Why?
|
| Young Adult | 42 | 2025 | 2464 | 1.270 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 9 | 2022 | 107 | 1.260 |
Why?
|
| Asthma | 4 | 2022 | 387 | 1.200 |
Why?
|
| Pandemics | 5 | 2024 | 287 | 1.170 |
Why?
|
| Hypertension | 7 | 2024 | 505 | 1.150 |
Why?
|
| Attitude of Health Personnel | 12 | 2020 | 214 | 1.080 |
Why?
|
| Blood Pressure | 5 | 2024 | 303 | 1.040 |
Why?
|
| Guideline Adherence | 8 | 2024 | 158 | 1.020 |
Why?
|
| Body Mass Index | 13 | 2022 | 967 | 1.010 |
Why?
|
| Measles | 3 | 2022 | 24 | 1.000 |
Why?
|
| Thrombocytopenia | 3 | 2022 | 15 | 0.990 |
Why?
|
| Data Collection | 16 | 2017 | 257 | 0.980 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 10 | 2025 | 88 | 0.950 |
Why?
|
| Obesity | 5 | 2022 | 842 | 0.950 |
Why?
|
| Middle Aged | 53 | 2025 | 8020 | 0.940 |
Why?
|
| Pneumococcal Vaccines | 8 | 2025 | 66 | 0.940 |
Why?
|
| Libraries, Medical | 1 | 2024 | 1 | 0.900 |
Why?
|
| Pregnancy | 20 | 2025 | 1529 | 0.850 |
Why?
|
| Whooping Cough | 7 | 2023 | 66 | 0.850 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2014 | 64 | 0.850 |
Why?
|
| Family Practice | 8 | 2015 | 45 | 0.840 |
Why?
|
| Eczema | 1 | 2022 | 7 | 0.820 |
Why?
|
| Product Surveillance, Postmarketing | 5 | 2014 | 95 | 0.800 |
Why?
|
| Pregnancy Complications, Infectious | 5 | 2025 | 146 | 0.800 |
Why?
|
| Disabled Persons | 1 | 2022 | 35 | 0.790 |
Why?
|
| Rotavirus Vaccines | 7 | 2025 | 52 | 0.780 |
Why?
|
| Delivery of Health Care | 6 | 2019 | 417 | 0.770 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 142 | 0.760 |
Why?
|
| Rural Population | 3 | 2020 | 52 | 0.750 |
Why?
|
| Infant, Newborn | 17 | 2025 | 858 | 0.730 |
Why?
|
| Ambulatory Care | 3 | 2020 | 247 | 0.710 |
Why?
|
| Ethnic Groups | 4 | 2019 | 485 | 0.700 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2020 | 2 | 0.690 |
Why?
|
| Population Surveillance | 8 | 2020 | 264 | 0.690 |
Why?
|
| Information Storage and Retrieval | 2 | 2020 | 14 | 0.690 |
Why?
|
| Geographic Information Systems | 1 | 2020 | 16 | 0.680 |
Why?
|
| Urinary Tract Infections | 1 | 2020 | 20 | 0.680 |
Why?
|
| Primary Health Care | 11 | 2024 | 770 | 0.650 |
Why?
|
| Disease Outbreaks | 3 | 2011 | 36 | 0.640 |
Why?
|
| Risk Assessment | 14 | 2022 | 1103 | 0.630 |
Why?
|
| Cohort Studies | 21 | 2023 | 2590 | 0.590 |
Why?
|
| Surveys and Questionnaires | 11 | 2025 | 1323 | 0.580 |
Why?
|
| Reimbursement Mechanisms | 2 | 2014 | 20 | 0.570 |
Why?
|
| Information Dissemination | 1 | 2017 | 51 | 0.570 |
Why?
|
| Urban Population | 2 | 2020 | 116 | 0.560 |
Why?
|
| Poliovirus Vaccine, Inactivated | 2 | 2014 | 21 | 0.550 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 2 | 2014 | 23 | 0.550 |
Why?
|
| Hepatitis B Vaccines | 3 | 2018 | 43 | 0.550 |
Why?
|
| Professional-Family Relations | 2 | 2015 | 49 | 0.540 |
Why?
|
| Treatment Refusal | 3 | 2013 | 33 | 0.530 |
Why?
|
| Cross-Sectional Studies | 13 | 2025 | 1335 | 0.530 |
Why?
|
| Prehypertension | 2 | 2013 | 22 | 0.530 |
Why?
|
| Aluminum | 3 | 2022 | 14 | 0.520 |
Why?
|
| Overweight | 5 | 2020 | 270 | 0.520 |
Why?
|
| Databases, Pharmaceutical | 1 | 2016 | 6 | 0.520 |
Why?
|
| Quality Assurance, Health Care | 3 | 2014 | 169 | 0.520 |
Why?
|
| Computers, Handheld | 1 | 2016 | 11 | 0.510 |
Why?
|
| Incidence | 13 | 2021 | 1269 | 0.510 |
Why?
|
| Heart Defects, Congenital | 3 | 2020 | 37 | 0.510 |
Why?
|
| Aged | 22 | 2025 | 6173 | 0.510 |
Why?
|
| Chronic Disease | 5 | 2022 | 428 | 0.500 |
Why?
|
| Decision Making | 2 | 2015 | 184 | 0.500 |
Why?
|
| Consumer Health Information | 1 | 2015 | 14 | 0.500 |
Why?
|
| Vaccines, Attenuated | 6 | 2023 | 45 | 0.490 |
Why?
|
| Pregnancy Outcome | 4 | 2024 | 158 | 0.470 |
Why?
|
| Herpes Zoster Vaccine | 5 | 2023 | 59 | 0.460 |
Why?
|
| Central Nervous System Stimulants | 1 | 2014 | 27 | 0.450 |
Why?
|
| Pneumococcal Infections | 2 | 2022 | 42 | 0.440 |
Why?
|
| Patient Compliance | 1 | 2016 | 301 | 0.440 |
Why?
|
| Deductibles and Coinsurance | 1 | 2014 | 30 | 0.440 |
Why?
|
| Databases, Factual | 6 | 2025 | 315 | 0.440 |
Why?
|
| Health Care Surveys | 8 | 2013 | 230 | 0.440 |
Why?
|
| Trust | 1 | 2013 | 31 | 0.430 |
Why?
|
| Dental Hygienists | 1 | 2013 | 1 | 0.430 |
Why?
|
| Drug Approval | 6 | 2021 | 12 | 0.430 |
Why?
|
| Firearms | 2 | 2024 | 32 | 0.420 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 197 | 0.420 |
Why?
|
| Multivariate Analysis | 6 | 2013 | 569 | 0.420 |
Why?
|
| Age Factors | 9 | 2020 | 923 | 0.420 |
Why?
|
| Premature Birth | 3 | 2024 | 137 | 0.410 |
Why?
|
| Registries | 6 | 2011 | 472 | 0.400 |
Why?
|
| Patient-Centered Care | 2 | 2013 | 197 | 0.400 |
Why?
|
| Community Health Services | 1 | 2013 | 83 | 0.400 |
Why?
|
| Myocarditis | 2 | 2022 | 14 | 0.390 |
Why?
|
| Case-Control Studies | 13 | 2024 | 1120 | 0.380 |
Why?
|
| Safety | 4 | 2016 | 41 | 0.380 |
Why?
|
| Health Services | 2 | 2013 | 113 | 0.380 |
Why?
|
| Tetanus | 2 | 2023 | 17 | 0.370 |
Why?
|
| Montana | 2 | 2021 | 2 | 0.370 |
Why?
|
| Haemophilus Vaccines | 3 | 2020 | 17 | 0.370 |
Why?
|
| Mass Screening | 2 | 2014 | 678 | 0.370 |
Why?
|
| Pregnancy Complications | 3 | 1998 | 201 | 0.360 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2008 | 39 | 0.360 |
Why?
|
| Licensure, Medical | 1 | 2010 | 2 | 0.360 |
Why?
|
| Hepatitis B | 2 | 2018 | 42 | 0.350 |
Why?
|
| Herpes Zoster | 3 | 2023 | 82 | 0.340 |
Why?
|
| Substance-Related Disorders | 4 | 2001 | 434 | 0.340 |
Why?
|
| Hospitalization | 6 | 2024 | 810 | 0.340 |
Why?
|
| Pediatric Obesity | 3 | 2017 | 85 | 0.340 |
Why?
|
| Vaccines, Inactivated | 5 | 2020 | 67 | 0.340 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2021 | 121 | 0.330 |
Why?
|
| Immunization, Secondary | 5 | 2025 | 57 | 0.320 |
Why?
|
| Insurance, Health, Reimbursement | 3 | 2014 | 11 | 0.320 |
Why?
|
| Seizures | 3 | 2014 | 29 | 0.320 |
Why?
|
| Accidents | 1 | 2008 | 2 | 0.310 |
Why?
|
| Mothers | 2 | 2002 | 106 | 0.310 |
Why?
|
| Absenteeism | 1 | 2008 | 24 | 0.310 |
Why?
|
| Natural Language Processing | 2 | 2019 | 58 | 0.310 |
Why?
|
| Attitude to Health | 3 | 2014 | 165 | 0.300 |
Why?
|
| Cost of Illness | 1 | 2008 | 93 | 0.290 |
Why?
|
| Logistic Models | 6 | 2013 | 928 | 0.280 |
Why?
|
| Rotavirus Infections | 3 | 2021 | 31 | 0.280 |
Why?
|
| Time Factors | 11 | 2022 | 1097 | 0.280 |
Why?
|
| Prospective Studies | 8 | 2023 | 1286 | 0.280 |
Why?
|
| Vaccines, Synthetic | 3 | 2021 | 34 | 0.280 |
Why?
|
| Models, Theoretical | 2 | 2020 | 70 | 0.280 |
Why?
|
| Prevalence | 9 | 2022 | 888 | 0.280 |
Why?
|
| Risk Factors | 10 | 2020 | 3362 | 0.280 |
Why?
|
| Bias | 4 | 2020 | 103 | 0.270 |
Why?
|
| Vaccines, Combined | 4 | 2023 | 80 | 0.260 |
Why?
|
| Proportional Hazards Models | 5 | 2021 | 711 | 0.260 |
Why?
|
| Travel | 2 | 2023 | 10 | 0.260 |
Why?
|
| Severity of Illness Index | 3 | 2024 | 455 | 0.260 |
Why?
|
| Gastrointestinal Diseases | 3 | 2018 | 27 | 0.250 |
Why?
|
| Physicians, Family | 3 | 2011 | 44 | 0.250 |
Why?
|
| Antihypertensive Agents | 2 | 2024 | 161 | 0.250 |
Why?
|
| Physicians | 4 | 2012 | 138 | 0.250 |
Why?
|
| Infant, Small for Gestational Age | 2 | 2024 | 57 | 0.250 |
Why?
|
| Internal Medicine | 3 | 2010 | 20 | 0.240 |
Why?
|
| Regression Analysis | 3 | 2014 | 300 | 0.240 |
Why?
|
| Hispanic Americans | 3 | 2017 | 404 | 0.240 |
Why?
|
| Guillain-Barre Syndrome | 3 | 2014 | 15 | 0.230 |
Why?
|
| Wounds, Gunshot | 1 | 2024 | 19 | 0.230 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 4 | 2022 | 62 | 0.230 |
Why?
|
| Pregnancy Trimester, First | 1 | 2024 | 40 | 0.230 |
Why?
|
| Stillbirth | 1 | 2024 | 29 | 0.230 |
Why?
|
| African Americans | 3 | 2017 | 472 | 0.230 |
Why?
|
| Checklist | 1 | 2024 | 15 | 0.230 |
Why?
|
| Cultural Diversity | 1 | 2024 | 17 | 0.220 |
Why?
|
| Insurance, Health | 3 | 2014 | 183 | 0.220 |
Why?
|
| Aged, 80 and over | 9 | 2024 | 1931 | 0.220 |
Why?
|
| Language | 1 | 2024 | 53 | 0.220 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 3 | 2013 | 52 | 0.220 |
Why?
|
| Burkitt Lymphoma | 1 | 2003 | 1 | 0.220 |
Why?
|
| Epidural Neoplasms | 1 | 2003 | 1 | 0.220 |
Why?
|
| Chorioamnionitis | 1 | 2023 | 18 | 0.210 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 720 | 0.210 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2022 | 4 | 0.210 |
Why?
|
| Sex Factors | 4 | 2021 | 644 | 0.210 |
Why?
|
| Urticaria | 1 | 2022 | 2 | 0.210 |
Why?
|
| Exanthema | 1 | 2022 | 7 | 0.210 |
Why?
|
| Drug Prescriptions | 1 | 2024 | 151 | 0.210 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2022 | 18 | 0.210 |
Why?
|
| Library Surveys | 1 | 2022 | 1 | 0.210 |
Why?
|
| Cholera | 1 | 2022 | 1 | 0.210 |
Why?
|
| Cholera Vaccines | 1 | 2022 | 1 | 0.210 |
Why?
|
| Abortion, Spontaneous | 1 | 2023 | 47 | 0.210 |
Why?
|
| Typhoid-Paratyphoid Vaccines | 1 | 2022 | 3 | 0.210 |
Why?
|
| Dermatitis, Atopic | 1 | 2022 | 13 | 0.210 |
Why?
|
| Sentinel Surveillance | 2 | 2016 | 12 | 0.200 |
Why?
|
| Managed Care Programs | 5 | 2015 | 325 | 0.200 |
Why?
|
| Minnesota | 3 | 2017 | 53 | 0.200 |
Why?
|
| Health Planning Guidelines | 1 | 2022 | 8 | 0.200 |
Why?
|
| Antigens | 2 | 2021 | 7 | 0.200 |
Why?
|
| Neural Tube Defects | 1 | 2002 | 8 | 0.200 |
Why?
|
| Anaphylaxis | 2 | 2019 | 15 | 0.200 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2014 | 125 | 0.200 |
Why?
|
| Immunologic Factors | 1 | 2022 | 29 | 0.190 |
Why?
|
| Chickenpox Vaccine | 4 | 2022 | 91 | 0.190 |
Why?
|
| Mexican Americans | 1 | 2002 | 45 | 0.190 |
Why?
|
| Seizures, Febrile | 1 | 2022 | 42 | 0.190 |
Why?
|
| Hepatitis A Vaccines | 2 | 2019 | 14 | 0.190 |
Why?
|
| Socioeconomic Factors | 2 | 2020 | 630 | 0.190 |
Why?
|
| Thrombosis | 1 | 2021 | 11 | 0.190 |
Why?
|
| Infant, Premature | 1 | 2022 | 60 | 0.190 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 17 | 0.190 |
Why?
|
| Rotavirus | 1 | 2021 | 18 | 0.190 |
Why?
|
| Models, Statistical | 3 | 2023 | 178 | 0.180 |
Why?
|
| Patient Participation | 2 | 2012 | 134 | 0.180 |
Why?
|
| Pregnant Women | 1 | 2021 | 45 | 0.180 |
Why?
|
| Vaccines, Conjugate | 4 | 2022 | 59 | 0.180 |
Why?
|
| Bursitis | 1 | 2020 | 4 | 0.180 |
Why?
|
| Shoulder Joint | 1 | 2020 | 5 | 0.180 |
Why?
|
| Intention | 1 | 2020 | 28 | 0.180 |
Why?
|
| Environment | 1 | 2020 | 52 | 0.180 |
Why?
|
| Germ-Line Mutation | 1 | 2010 | 18 | 0.180 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2010 | 20 | 0.170 |
Why?
|
| Cephalexin | 1 | 2020 | 1 | 0.170 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2020 | 2 | 0.170 |
Why?
|
| Cystitis | 1 | 2020 | 2 | 0.170 |
Why?
|
| Pyelonephritis | 1 | 2020 | 3 | 0.170 |
Why?
|
| Weight Loss | 2 | 2019 | 305 | 0.170 |
Why?
|
| Medical Record Linkage | 1 | 2020 | 38 | 0.170 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2020 | 25 | 0.170 |
Why?
|
| Communicable Diseases | 1 | 2020 | 15 | 0.170 |
Why?
|
| Pilot Projects | 2 | 2022 | 219 | 0.170 |
Why?
|
| Suicide | 1 | 2021 | 124 | 0.170 |
Why?
|
| Epidemiological Monitoring | 1 | 2019 | 25 | 0.170 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 381 | 0.170 |
Why?
|
| Hepatitis A Virus, Human | 1 | 2019 | 5 | 0.170 |
Why?
|
| Hepatitis A | 1 | 2019 | 10 | 0.170 |
Why?
|
| Meningitis, Pneumococcal | 1 | 1999 | 3 | 0.170 |
Why?
|
| Anti-Obesity Agents | 1 | 2019 | 18 | 0.170 |
Why?
|
| Phentermine | 1 | 2019 | 10 | 0.160 |
Why?
|
| Seasons | 6 | 2020 | 105 | 0.160 |
Why?
|
| Appetite Depressants | 1 | 2019 | 16 | 0.160 |
Why?
|
| Medicaid | 4 | 2025 | 190 | 0.160 |
Why?
|
| Poisson Distribution | 3 | 2014 | 88 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 56 | 0.160 |
Why?
|
| Autism Spectrum Disorder | 1 | 2022 | 164 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 3 | 2015 | 250 | 0.160 |
Why?
|
| Osteoporosis, Postmenopausal | 4 | 1999 | 43 | 0.160 |
Why?
|
| RNA, Messenger | 3 | 2023 | 72 | 0.160 |
Why?
|
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 2 | 2015 | 32 | 0.150 |
Why?
|
| Odds Ratio | 6 | 2017 | 673 | 0.150 |
Why?
|
| Blood Pressure Determination | 2 | 2015 | 57 | 0.150 |
Why?
|
| Maternal Health Services | 1 | 1998 | 13 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 376 | 0.150 |
Why?
|
| Infection | 1 | 2018 | 17 | 0.150 |
Why?
|
| Health Status Disparities | 1 | 2019 | 147 | 0.150 |
Why?
|
| Parental Consent | 2 | 2014 | 3 | 0.140 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2017 | 22 | 0.140 |
Why?
|
| Health Services Research | 4 | 2011 | 232 | 0.140 |
Why?
|
| United States Food and Drug Administration | 3 | 2021 | 34 | 0.140 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 368 | 0.140 |
Why?
|
| Diastole | 1 | 2017 | 5 | 0.140 |
Why?
|
| Respiratory Tract Infections | 2 | 2018 | 50 | 0.140 |
Why?
|
| Systole | 1 | 2017 | 22 | 0.140 |
Why?
|
| Health Surveys | 4 | 2017 | 261 | 0.140 |
Why?
|
| Child Abuse, Sexual | 1 | 1997 | 14 | 0.140 |
Why?
|
| Oceanic Ancestry Group | 1 | 2017 | 33 | 0.140 |
Why?
|
| Needs Assessment | 1 | 2017 | 69 | 0.140 |
Why?
|
| Focus Groups | 2 | 2014 | 147 | 0.130 |
Why?
|
| Computer Simulation | 2 | 2013 | 82 | 0.130 |
Why?
|
| Health Services Needs and Demand | 1 | 1997 | 93 | 0.130 |
Why?
|
| Risk | 5 | 2020 | 518 | 0.130 |
Why?
|
| Centers for Disease Control and Prevention (U.S.) | 1 | 2016 | 32 | 0.130 |
Why?
|
| Thinness | 2 | 2015 | 30 | 0.130 |
Why?
|
| Asian Americans | 1 | 2017 | 176 | 0.130 |
Why?
|
| Adjuvants, Immunologic | 1 | 2015 | 16 | 0.130 |
Why?
|
| Data Accuracy | 1 | 2016 | 27 | 0.130 |
Why?
|
| Public Health Surveillance | 3 | 2020 | 42 | 0.120 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2021 | 537 | 0.120 |
Why?
|
| Health Maintenance Organizations | 2 | 2014 | 417 | 0.120 |
Why?
|
| Venous Thromboembolism | 1 | 2015 | 53 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 487 | 0.120 |
Why?
|
| Transition to Adult Care | 1 | 2015 | 11 | 0.120 |
Why?
|
| Environmental Exposure | 1 | 2015 | 117 | 0.120 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 1219 | 0.120 |
Why?
|
| Social Welfare | 1 | 2014 | 13 | 0.120 |
Why?
|
| Contraceptives, Oral | 1 | 2014 | 26 | 0.120 |
Why?
|
| Direct Service Costs | 1 | 2014 | 8 | 0.110 |
Why?
|
| California | 2 | 2019 | 2328 | 0.110 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 186 | 0.110 |
Why?
|
| Costs and Cost Analysis | 1 | 2014 | 80 | 0.110 |
Why?
|
| Communication | 1 | 2015 | 194 | 0.110 |
Why?
|
| Dyslipidemias | 1 | 2014 | 62 | 0.110 |
Why?
|
| Cardiovascular Diseases | 2 | 2017 | 599 | 0.110 |
Why?
|
| Confidence Intervals | 3 | 2021 | 237 | 0.110 |
Why?
|
| Health Care Costs | 2 | 2014 | 229 | 0.110 |
Why?
|
| Health Services Accessibility | 2 | 2009 | 292 | 0.110 |
Why?
|
| Research Design | 3 | 2022 | 376 | 0.110 |
Why?
|
| Parenting | 1 | 2013 | 29 | 0.100 |
Why?
|
| Data Mining | 2 | 2022 | 17 | 0.100 |
Why?
|
| Feasibility Studies | 1 | 2013 | 114 | 0.100 |
Why?
|
| Patient Education as Topic | 2 | 2011 | 213 | 0.100 |
Why?
|
| Maternal Age | 2 | 2023 | 77 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 957 | 0.100 |
Why?
|
| Physicians, Primary Care | 1 | 2013 | 72 | 0.100 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2012 | 5 | 0.100 |
Why?
|
| Anemia, Sickle Cell | 1 | 2011 | 9 | 0.100 |
Why?
|
| Comorbidity | 3 | 2016 | 597 | 0.100 |
Why?
|
| Bone Density | 4 | 1999 | 97 | 0.090 |
Why?
|
| Syncope | 1 | 2011 | 12 | 0.090 |
Why?
|
| Meningococcal Vaccines | 3 | 2022 | 39 | 0.090 |
Why?
|
| Mass Vaccination | 1 | 2011 | 22 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 305 | 0.090 |
Why?
|
| Alendronate | 3 | 1999 | 15 | 0.090 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2010 | 13 | 0.090 |
Why?
|
| Health Promotion | 1 | 2013 | 281 | 0.090 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2010 | 1 | 0.090 |
Why?
|
| Haemophilus influenzae | 1 | 2010 | 1 | 0.090 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2010 | 1 | 0.090 |
Why?
|
| Drug Recalls | 1 | 2010 | 1 | 0.090 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2011 | 85 | 0.090 |
Why?
|
| Haemophilus Infections | 1 | 2010 | 5 | 0.090 |
Why?
|
| Medicare Part D | 1 | 2010 | 15 | 0.090 |
Why?
|
| Autistic Disorder | 1 | 2011 | 100 | 0.090 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 37 | 0.090 |
Why?
|
| Chi-Square Distribution | 2 | 2002 | 154 | 0.080 |
Why?
|
| Chickenpox | 1 | 2010 | 35 | 0.080 |
Why?
|
| Pertussis Vaccine | 1 | 2009 | 14 | 0.080 |
Why?
|
| Quebec | 1 | 2008 | 2 | 0.080 |
Why?
|
| Efficiency | 1 | 2008 | 13 | 0.080 |
Why?
|
| Self-Assessment | 1 | 2008 | 14 | 0.080 |
Why?
|
| Risk-Taking | 1 | 2009 | 109 | 0.080 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2008 | 12 | 0.070 |
Why?
|
| Herpesvirus 3, Human | 2 | 2023 | 44 | 0.070 |
Why?
|
| Postal Service | 2 | 2008 | 73 | 0.070 |
Why?
|
| Tetanus Toxoid | 2 | 2012 | 11 | 0.070 |
Why?
|
| Patient Selection | 1 | 2007 | 190 | 0.070 |
Why?
|
| Health Status | 1 | 2008 | 299 | 0.070 |
Why?
|
| Self-Help Groups | 1 | 2006 | 30 | 0.060 |
Why?
|
| Rural Health | 1 | 2005 | 8 | 0.060 |
Why?
|
| Urban Health | 1 | 2005 | 38 | 0.060 |
Why?
|
| Probability | 1 | 2005 | 79 | 0.060 |
Why?
|
| Live Birth | 1 | 2024 | 9 | 0.060 |
Why?
|
| Congenital Abnormalities | 1 | 2024 | 26 | 0.060 |
Why?
|
| Referral and Consultation | 1 | 2006 | 169 | 0.060 |
Why?
|
| Public Health Practice | 1 | 2004 | 13 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 2 | 2021 | 77 | 0.060 |
Why?
|
| Calcium Channel Blockers | 1 | 2024 | 14 | 0.060 |
Why?
|
| Office Automation | 1 | 2004 | 3 | 0.060 |
Why?
|
| Patient Care | 1 | 2004 | 35 | 0.060 |
Why?
|
| Spinal Cord Compression | 1 | 2003 | 1 | 0.050 |
Why?
|
| Epidural Space | 1 | 2003 | 2 | 0.050 |
Why?
|
| Toxoids | 1 | 2023 | 3 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2024 | 105 | 0.050 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2023 | 21 | 0.050 |
Why?
|
| International Classification of Diseases | 1 | 2004 | 85 | 0.050 |
Why?
|
| Family Characteristics | 1 | 2023 | 55 | 0.050 |
Why?
|
| Health Policy | 1 | 2004 | 123 | 0.050 |
Why?
|
| Drug Utilization | 2 | 2013 | 128 | 0.050 |
Why?
|
| European Continental Ancestry Group | 2 | 2013 | 529 | 0.050 |
Why?
|
| Antacids | 1 | 2022 | 1 | 0.050 |
Why?
|
| Blood Group Antigens | 1 | 2022 | 1 | 0.050 |
Why?
|
| Vibrio cholerae O1 | 1 | 2022 | 1 | 0.050 |
Why?
|
| Dehydration | 1 | 2022 | 2 | 0.050 |
Why?
|
| Water | 1 | 2022 | 2 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 50 | 0.050 |
Why?
|
| Travel-Related Illness | 1 | 2022 | 3 | 0.050 |
Why?
|
| Poverty Areas | 1 | 2002 | 21 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2003 | 47 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2022 | 90 | 0.050 |
Why?
|
| Self Report | 1 | 2024 | 253 | 0.050 |
Why?
|
| Measles Vaccine | 1 | 2022 | 17 | 0.050 |
Why?
|
| Information Systems | 1 | 2021 | 22 | 0.050 |
Why?
|
| Fever | 1 | 2022 | 55 | 0.050 |
Why?
|
| State Health Plans | 1 | 2001 | 35 | 0.050 |
Why?
|
| Telephone | 1 | 2002 | 161 | 0.050 |
Why?
|
| Patient Safety | 1 | 2022 | 39 | 0.050 |
Why?
|
| Massachusetts | 2 | 2001 | 94 | 0.050 |
Why?
|
| Safety-Based Drug Withdrawals | 1 | 2021 | 1 | 0.050 |
Why?
|
| Educational Status | 1 | 2002 | 200 | 0.050 |
Why?
|
| Gestational Age | 1 | 2021 | 112 | 0.050 |
Why?
|
| Drug Labeling | 1 | 2021 | 14 | 0.050 |
Why?
|
| Evidence-Based Practice | 1 | 2021 | 46 | 0.050 |
Why?
|
| Office Visits | 2 | 2015 | 80 | 0.050 |
Why?
|
| Bacterial Capsules | 1 | 2020 | 5 | 0.050 |
Why?
|
| Health Expenditures | 1 | 2001 | 76 | 0.040 |
Why?
|
| Child Health Services | 1 | 2022 | 113 | 0.040 |
Why?
|
| Epidemiologic Research Design | 2 | 2013 | 18 | 0.040 |
Why?
|
| Prescriptions | 1 | 2020 | 27 | 0.040 |
Why?
|
| Deltoid Muscle | 1 | 2020 | 4 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2020 | 10 | 0.040 |
Why?
|
| Morbidity | 1 | 2020 | 59 | 0.040 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2010 | 1 | 0.040 |
Why?
|
| Australia | 1 | 2010 | 23 | 0.040 |
Why?
|
| Population Groups | 1 | 2010 | 8 | 0.040 |
Why?
|
| Insurance Claim Reporting | 1 | 2020 | 7 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2010 | 44 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 329 | 0.040 |
Why?
|
| Drug Hypersensitivity | 1 | 2019 | 10 | 0.040 |
Why?
|
| Progestins | 1 | 1999 | 25 | 0.040 |
Why?
|
| Appendicitis | 1 | 2019 | 15 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2019 | 24 | 0.040 |
Why?
|
| Mental Health Services | 1 | 2001 | 159 | 0.040 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1999 | 1 | 0.040 |
Why?
|
| Spinal Puncture | 1 | 1999 | 2 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2010 | 50 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 2019 | 81 | 0.040 |
Why?
|
| Estrogens | 1 | 1999 | 61 | 0.040 |
Why?
|
| Medical Informatics | 1 | 2019 | 38 | 0.040 |
Why?
|
| Family | 1 | 2010 | 112 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 2000 | 124 | 0.040 |
Why?
|
| Linear Models | 1 | 2019 | 232 | 0.040 |
Why?
|
| Pancreatitis | 1 | 2019 | 50 | 0.040 |
Why?
|
| Minority Groups | 1 | 2019 | 101 | 0.040 |
Why?
|
| Prognosis | 1 | 2020 | 609 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 354 | 0.040 |
Why?
|
| Prediabetic State | 1 | 2019 | 56 | 0.040 |
Why?
|
| Calcium, Dietary | 1 | 1998 | 27 | 0.040 |
Why?
|
| Sepsis | 1 | 1999 | 70 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2012 | 1265 | 0.040 |
Why?
|
| Croup | 1 | 2018 | 4 | 0.040 |
Why?
|
| Medroxyprogesterone | 1 | 1998 | 2 | 0.040 |
Why?
|
| Otitis Media | 1 | 2018 | 19 | 0.040 |
Why?
|
| Episode of Care | 1 | 1998 | 14 | 0.040 |
Why?
|
| Maternal Welfare | 1 | 1998 | 14 | 0.040 |
Why?
|
| Patient Dropouts | 1 | 1998 | 22 | 0.040 |
Why?
|
| Centers for Medicare and Medicaid Services (U.S.) | 1 | 1997 | 5 | 0.040 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 1997 | 28 | 0.040 |
Why?
|
| Recurrence | 1 | 1998 | 189 | 0.040 |
Why?
|
| Survival Analysis | 1 | 1998 | 216 | 0.040 |
Why?
|
| Respiratory Sounds | 1 | 2017 | 12 | 0.040 |
Why?
|
| Length of Stay | 1 | 1998 | 182 | 0.030 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 1997 | 75 | 0.030 |
Why?
|
| Women's Health | 1 | 1998 | 202 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 118 | 0.030 |
Why?
|
| Demography | 2 | 2008 | 101 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 1997 | 147 | 0.030 |
Why?
|
| Public Health | 1 | 2017 | 81 | 0.030 |
Why?
|
| Patient Care Team | 1 | 1997 | 114 | 0.030 |
Why?
|
| Patient Readmission | 1 | 1998 | 164 | 0.030 |
Why?
|
| Government Programs | 1 | 2015 | 11 | 0.030 |
Why?
|
| Survival Rate | 1 | 2016 | 260 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 181 | 0.030 |
Why?
|
| Body Weight | 1 | 2016 | 224 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2015 | 106 | 0.030 |
Why?
|
| Mental Disorders | 1 | 1997 | 280 | 0.030 |
Why?
|
| Encephalitis | 1 | 2014 | 5 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2014 | 81 | 0.030 |
Why?
|
| Triglycerides | 1 | 2014 | 89 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2014 | 119 | 0.030 |
Why?
|
| Off-Label Use | 1 | 2013 | 14 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 2013 | 2 | 0.030 |
Why?
|
| Schools | 1 | 2014 | 87 | 0.030 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2013 | 7 | 0.030 |
Why?
|
| Physical Examination | 1 | 2013 | 20 | 0.030 |
Why?
|
| Quality Control | 1 | 2012 | 45 | 0.030 |
Why?
|
| Health Education | 1 | 2013 | 111 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2012 | 44 | 0.020 |
Why?
|
| Professional Practice Location | 1 | 2011 | 1 | 0.020 |
Why?
|
| Hypersensitivity | 1 | 2011 | 18 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2011 | 19 | 0.020 |
Why?
|
| Income | 1 | 2012 | 90 | 0.020 |
Why?
|
| Bell Palsy | 1 | 2011 | 14 | 0.020 |
Why?
|
| Pharmaceutical Services | 1 | 2011 | 34 | 0.020 |
Why?
|
| Job Satisfaction | 1 | 2011 | 21 | 0.020 |
Why?
|
| Health Behavior | 1 | 2013 | 360 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 92 | 0.020 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2010 | 15 | 0.020 |
Why?
|
| Fees, Pharmaceutical | 1 | 2010 | 2 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2011 | 305 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 1999 | 160 | 0.020 |
Why?
|
| Efficiency, Organizational | 1 | 2008 | 32 | 0.020 |
Why?
|
| Health Care Rationing | 1 | 2007 | 12 | 0.020 |
Why?
|
| Intussusception | 1 | 2007 | 16 | 0.020 |
Why?
|
| Perception | 1 | 2007 | 58 | 0.020 |
Why?
|
| Mass Media | 1 | 2005 | 17 | 0.010 |
Why?
|
| Policy Making | 1 | 2004 | 15 | 0.010 |
Why?
|
| Contract Services | 1 | 2001 | 4 | 0.010 |
Why?
|
| Mentally Ill Persons | 1 | 2001 | 3 | 0.010 |
Why?
|
| Sexuality | 1 | 2000 | 11 | 0.010 |
Why?
|
| Canada | 1 | 2000 | 66 | 0.010 |
Why?
|
| Pregnancy Trimesters | 1 | 2000 | 30 | 0.010 |
Why?
|
| Collagen Type I | 1 | 1999 | 6 | 0.010 |
Why?
|
| Collagen | 1 | 1999 | 7 | 0.010 |
Why?
|
| Peptides | 1 | 1999 | 12 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1999 | 115 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2001 | 326 | 0.010 |
Why?
|
| Forearm | 1 | 1998 | 1 | 0.010 |
Why?
|
| Progesterone Congeners | 1 | 1998 | 5 | 0.010 |
Why?
|
| Pelvic Bones | 1 | 1998 | 5 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 1998 | 19 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1998 | 43 | 0.010 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1998 | 99 | 0.010 |
Why?
|
| Postmenopause | 1 | 1998 | 243 | 0.010 |
Why?
|